ABSTRACT
Objective@#To evaluate the effects L-apigenin A on Alzheimer＇s disease(AD), and analyze the correlation between MMSE and ADAS-cog scores.@*Methods@#From January 2009 to December 2014, 34 patients with AD were selected in Qinhuangdao Military Industry Hospital.They were treated with celery seed extract L-apigenin.The MMSE scores and ADAS-cog scores were evaluated before treatment and 18, 36 and 72 d after treatment.The correlation between MMSE scores and ADAS-cog scores was analyzed.@*Results@#There were statistically significant differences in the MMSE scores between 72d after treatment[(22.59±1.13)points]and before treatment[(20.53±1.42)points], 18d after treatment[(20.44±1.24)points]and 36d after treatment[(20.97±1.17)points](t=6.619, 7.473, 5.807, all P<0.05). There were statistically significant differences in ADAS-Cog scores between 72d after treatment[(17.09±1.53)points]and before treatment[(20.47±2.85)points], 18d after treatment[(20.18±2.34)points]and 36d after treatment[(20.18±2.49)points](t=6.093, 6.445, 6.165, all P<0.05). The MMSE score and ADAS-Cog score had negative correlation by Pearson analysis (r=-0.259, P=0.000).@*Conclusion@#L-apigenin A can significantly improve the cognitive function of patients with AD.There is significant negative correlation between the MMSE scores and ADAS-cog scores.
ABSTRACT
Objective To evaluate the effects L-apigenin A on Alzheimer's disease(AD),and analyze the correlation between MMSE and ADAS-cog scores.Methods From January 2009 to December 2014,34 patients with AD were selected in Qinhuangdao Military Industry Hospital.They were treated with celery seed extract L-apigenin.The MMSE scores and ADAS-cog scores were evaluated before treatment and 18,36 and 72 d after treatment.The correlation between MMSE scores and ADAS-cog scores was analyzed.Results There were statistically significant differences in the MMSE scores between 72d after treatment [(22.59 ± 1.13)points] and before treatment [(20.53 ±1.42) points],18d after treatment [(20.44 ± 1.24) points] and 36d after treatment [(20.97 ± 1.17) points] (t =6.619,7.473,5.807,all P ＜ 0.05).There were statistically significant differences in ADAS-Cog scores between 72d after treatment[(17.09 ± 1.53) points] and before treatment [(20.47 ± 2.85) points],18d after treatment [(20.18 ± 2.34) points] and 36d after treatment [(20.18 ± 2.49) points] (t =6.093,6.445,6.165,all P ＜ 0.05).The MMSE score and ADAS-Cog score had negative correlation by Pearson analysis (r =-0.259,P =0.000).Conclusion L-apigenin A can significantly improve the cognitive function of patients with AD.There is significant negative correlation between the MMSE scores and ADAS-cog scores.
ABSTRACT
As a foreign body, intravascular stent will induce platelet aggregation on the stent surface and activate platelet system and coagulation system, resulting in thrombosis. Smooth muscle cells migrate to injured site and proliferate, leading to intimal hyperplasia and vessel wall remodeling, which induces restenosis. Incidence of intravascular restenosis is determined by stent type, disease of the host, severity of stenosis before implantation and remnant stenosis length following stenting. Inhibition of intimal hyperplasia or improvement of intima formation and vessel wall remodeling can effectively prevent restenosis. Currently, there are many drugs to prevent restenosis, including antiplatelet drug, anti-inflammatory growth factor inhibitor and anti-cell proliferation drugs.